7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

Please reload

Featured Posts

Potentia Pharmaceuticals Licenses Complement Inhibitor Compstatin from the University of Pennsylvania

July 27, 2006

Louisville, Ky. – Potentia Pharmaceuticals, Inc. announced today that it has entered into an exclusive, worldwide licensing agreement with the University of Pennsylvania that provides broad rights to develop and commercialize University of Pennsylvania's Compstatin class of complement-inhibiting peptides for the treatment of ocular diseases. While the terms of the license have not been disclosed, this agreement will allow Potentia to move forward with the preclinical development of the first complement-inhibiting drug product aimed at treating both the "wet" and "dry" forms of age-related macular degeneration (ARMD).


"We are excited to work with the University of Pennsylvania in developing the first treatment for macular degeneration based on the important genetic findings of the last year" said Cedric Francois, M.D., Ph.D., Chief Executive Officer for Potentia. "Genetic analysis of patients with macular degeneration has now clearly established that excessive complement activation is involved in the development of macular degeneration. Compstatin is one of the best complement-inhibiting drugs available and we look forward to evaluate its potential and to help patients suffering from this devastating disease."




Please reload